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The National Marrow Donor Program, in partnership with the American Society for Blood and Marrow
Transplantation, sponsored and organized a series of symposia to identify complex issues affecting the
delivery of hematopoietic cell transplantation (HCT) and to collaboratively develop options for solutions.
“Hematopoietic Cell Transplantation in 2020: A System Capacity Initiative” used a deliberative process model
to engage professional organizations, experts, transplant centers, and stakeholders in a national collaborative
effort. Year 2 efforts emphasized data analysis and identiﬁcation of innovative ideas to increase HCT system
efﬁciency, address future capacity requirements, and ensure adequate reimbursement for HCT programs to
meet the projected need for HCT. This report highlights the deliberations and recommendations of Year 2 and
the associated symposium held in September 2011.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION [1]. The program, now in its third year, has identiﬁed inno-
To better understand the status of existing personnel and
center infrastructure needed to support hematopoietic cell
transplantation (HCT) in the United States, and to address
system capacity challenges that would impede the future
growth of HCT, the National Marrow Donor Program (NMDP)
has sponsored and organized a series of multiyear symposia
to identify complex issues affecting the delivery of HCT and
collaboratively develop options for solutions. “Hematopoi-
etic Cell Transplantation in 2020: A System Capacity Initia-
tive” (SCI), organized by the NMDP in 2009 in partnership
with the American Society for Blood and Marrow Trans-
plantation (ASBMT), uses a deliberative process model to
engage professional organizations, experts, transplant
centers, and stakeholders in a national collaborative effortedgments on page 9.
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12.10.005vative ideas to increase efﬁciency using current capacity,
address future capacity requirements, and ensure adequate
reimbursement of HCT programs to meet the current and
projected need for HCT (Figure 1). Year 1 focused on needs
assessments and identiﬁcation of factors that would have the
greatest impact on future capacity. Year 2 emphasized data
analysis and the development of pilot projects to address
capacity issues. Year 3 will focus on establishing metrics for
program evaluation, implementing pilot demonstration
projects, and disseminating ﬁndings. Deliberations and
recommendations from year 1 have been published previ-
ously [2]. This report highlights the deliberations and
recommendations of year 2 and the associated symposium
held in September 2011. More details on the program are
available online at http://www.marrow.org/SCI.
DELIBERATIVE PROCESS
Pre-Symposium Year 2
Between October 2010 and September 2011, the SCI
Steering Committee, its Chair, and NMDP lead staff served toTransplantation.
Table 1
Figure 1. HCT in 2020: System Capacity Initiative. (Reprinted with permission. [1])
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(WGs). In year 2, the Steering Committee acknowledged the
need for a Pharmacy Workforce WG. As a result of the year 1
deliberations, the Steering Committee also determined that
the aims of the Facilities and Capacity and Care Delivery
Model WGs overlapped, and thus combined the 2 WGs for
year 2. The resulting 7 year 2WGswere PhysicianWorkforce,
Advanced Practice Professionals (APPs) Workforce, Nursing
Workforce, Pharmacy Workforce, Diversity and Health Care
Disparities, Facility Capacity and Care Delivery Model, and
Financial. Each WG comprised 13-20 key professionals,
representatives of academic organizations, thought leaders,
and stakeholders. The 7 WGs conducted their work via
monthly teleconferences over the year. The goal for year 2
was to analyze data from year 1 needs assessments and
collect additional data required to facilitate informed plan-
ning and implementation of recommended initiatives.HCT Workforce Challenges: Common Themes among System Capacity
Initiative Workforce Working Groups
Recruitment
 Expose students and residents to HCT earlier in career.
 Identify HCT as a career path for fellows and junior professionals.
 Create shadow/clinical rotation opportunities for those interested in
BMT.
 Improve training curricula and provide educational resources.
Retention
 Address dissatisfaction with work/life balance (eg, provider-to-
patient ratios, ﬂexible work schedules, multidisciplinary stafﬁng
models, ability to use vacation time).
 Identify range of experience with HCT (eg, inpatient, outpatient,
decision making) and success stories.
 Promote professional development (eg, support for professional
memberships, coverage for licenses/fees) and educational
opportunities from orientation to advanced HCT courses.
 Provide mentoring/coaching early in career.
 Improve the work environment through recognition, addressing
compassion fatigue and moral/ethical distress, and protected time
for research.
Diversity
 Increase cultural competence among all HCT health professionals.
 Expand diversity of the workforce to represent communities in need
of HCT.
 Integrate Culturally and Linguistically Appropriate Services
standards.Year 2 Symposium
All WGs convened in September 2011 for a 1-1/2-day
symposium in Minneapolis, Minnesota. The WGs presented
progress reports and prioritized initiatives, then elicited
feedback through audience polling and round table discus-
sions. Before the symposium, the WGs analyzed initiatives to
determinepriorities basedon (1)beneﬁts to increasing system
capacity; (2) resources needed, costs, and organizations to
engage; (3) potential challenges to implementation; and (4)
metrics to determine effectiveness of the initiative. Additional
prioritizationoccurredvia audiencepolling at the symposium,
with a speciﬁc focus on rating each initiative for potential
impact, role of the NMDP in implementation, and estimated
time required to complete the initiative. Round table discus-
sion notes were qualitatively analyzed for saturation of
themesacross theworkforceWGs. Common themes regarding
the challenges faced by the HCT workforce were summarized
(Table 1). As follow-up to the year 1 symposium, a special
presentation on ethical issues inherent in HCT addressed
challenges speciﬁc to the work environment, compassion
fatigue, and burnout experienced by the HCT workforce.PRIORITIZED INITIATIVES BY WORKING GROUP
Here we describe the initiatives for each WG that received
thehighest priority ratings by symposiumattendees (Figure 2).Physician Workforce
1. Develop and implement elective course for fourth-year
medical school students and ﬁrst/second-year residents.
Findings from group interviews of fellows conducted
during year 1 underscored the importance of early
exposure to HCT in physicians’ career paths. The
course will provide earlier exposure to HCT as a career
and is intended to positively inﬂuence career paths.
Key components of the rotationwill expose the learner
to outpatient HCT care, survivorship issues, decision
Figure 2. System Capacity Initiative workforce recommendations: impact on capacity.
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provided by an HCT career, the science related to HCT,
and mentorship opportunities.
2. Develop and implement an HCT Program Directors’ track
at BMT Tandem Meetings.
This forum would provide a resource for education on
and discussion of issues related to fellow training in
HCT. An inaugural meeting was organized as part of
the 2012 BMT Tandem Meetings.
3. Disseminate results of group interviews on workforce,
recruitment, and retention conducted with Fellowship
Program Directors and fellows.
The group interviews and needs assessment surveys
were very informative. Key ﬁndings show that earlier
exposure to HCT and mentoring are critical, work/life
balance is an important consideration for a career in
HCT, and training/curriculum needs improvement and
standardization. Results from the Transplant Provider
and Center Factors Survey, currently in the ﬁeld, will
direct initiatives to address these ﬁndings. Wider
dissemination of results will inform the broader HCT
community of barriers to physician recruitment and
retention.
Advanced Practice Professionals Workforce
1. Develop a Web page for advanced practice professionals
(APPs) within the ASBMT Web site.
The goal of this initiative is to centralize HCT
resources for APPs and others interested in the
profession. This Web site will increase visibility of job
postings, education resources, student rotations, and
networking opportunities. It will serve as a nationallyrecognized resource for transplant center staff (eg,
HCT program directors, physicians, administrators)
and help build collaboration and maintain effective
relationships between HCT APPs and physicians.
2. Create and disseminate a brochure for APPs that
promotes career options in HCT.
The APP WG has devoted a signiﬁcant amount of time
to developing recommendations for the Optimal Work
Model, speciﬁcally deﬁning the role of APPs within the
HCT care team. The Optimal Work Model brochure is
intended to assist established and student APPs
considering entering the ﬁeld, as well as APPs
currently practicing in HCT or other disciplines, in
learning more about how to best use APPs in HCT.
Highlights from the brochure include the following
important topics: description of APPs’ contribution to
the HCT care team, work hours and schedules, multi-
disciplinary support staff, patient care models, salary
and compensation, and professional development and
nonclinical APP support.
3. Engage HCT programs to increase the number of shad-
owing and clinical rotation opportunities for APPs.
The WG assessed the APP student education initiative,
HCT 101 lecture, piloted by the WG in year 2. The
pilot was designed to promote recruitment of APP
students and APPs practicing in non-HCT ﬁelds to
a career in HCT (n¼ 49). Preliminary data showed that
43% of the students were not previously familiar with
the HCT profession, and that after the lecture, 37%
were “likely or very likely to pursue a career in HCT.”
The long-term vision is to make educational oppor-
tunities such as this available through the ASBMT APP
Web site.
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1. Develop the “Introduction to Blood and Marrow Trans-
plantation (BMT)” presentation.
This initiative focused on outreach to senior students
in accredited nursing programs. The presentation and
learning objectives highlight HCTas a career option for
nursing students as well as nurses not currently
practicing within the HCT specialty.
2. Develop a program to address ethical/moral distress.
Year 1 survey results identiﬁed moral and ethical
distress and compassion fatigue as major issues
among nurses. Professional caregivers experience
anxiety, frustration, and pressure related to their work
and often have no outlets to discuss these experiences
or difﬁcult patient care communication issues with
their healthcare professional peers [3]. One approach
to addressing these issues is implementing multidis-
ciplinary rounds (eg, Schwartz Center rounds, ethics
rounds) to provide an opportunity to discuss ethical
concerns or share feelings about cases relating to local/
national issues.
An exploratory session on ethical case studies was
held during the year 2 symposium. Amultidisciplinary
subgroup was tasked with developing recommenda-
tions for discussing moral and ethical issues related to
speciﬁc points of care in the HCT continuum, from
preparation for HCT to survivorship.
3. Increase the diversity of the HCT nursing workforce.
The WG plans to make outreach to culturally diverse
nursing associations and conferences (eg, Interna-
tional Cultural Cancer Conference, National Coalition
of Ethnic and Minority Nurse Associations, National
Black Nurses Association) to expose nurses from
diverse communities to HCT as a career path option.
Strategies to successfully engage these nurses include
disseminating culturally appropriate information on
how a HCT nursing workforce interested in and qual-
iﬁed to serve diverse and underserved populations can
increase access to transplant.
Pharmacy Workforce
1. Provide training opportunities for pharmacists.
The WG recommended development of training
courses for HCT pharmacists to be offered at profes-
sional meetings and/or online. These courses would
highlight career opportunities within HCT and aim to
expand the knowledge base and improve the skill set
of HCT pharmacists. The WG will create a full-day HCT
course for new pharmacists, intermediate pharma-
cists, and resident/seasoned pharmacists.
2. Deﬁne a minimum standard of pharmaceutical care.
The level of pharmaceutical care provided for patients
at transplant centers across the United States
(both inpatient and outpatient) varies widely. A
deﬁned minimum standard of pharmaceutical care,
endorsed by accreditation organizations (eg, Founda-
tion for the Accreditation of Cellular Therapy),
would provide a stafﬁng benchmark and improve
consistency of care nationally. Centers would be
required to adhere to this benchmark to obtain and
maintain accreditation.
3. Develop and use collaborative practice agreements
(CPAs).The intent of CPAs is to authorize the pharmacist to
work in a collaborative fashion with the physician.
CPAs set forth guidelines for collaboration between
the physician and pharmacist. Through this initia-
tive, the WG will (1) identify transplant centers that
currently use CPA; (2) arrange for presentations at
the upcoming ASBMT/Center for International Blood
and Marrow Transplant Research (CIBMTR) BMT
Tandem Meetings to provide sample agreements,
instructions on how to implement CPAs, and best
practices; (3) publish evaluation outcomes from
transplant centers that successfully use CPA; (4)
encourage transplant centers to develop goals of
pharmaceutical therapy and a CPA; (5) formally
recommend that CPAs be evidence-based and
include provisions for management of acute exacer-
bations of disease; and (6) pilot the development
and use of CPAs.Finance
The Financial WG acknowledged that health insurance
coverage and beneﬁts for transplantation remain highly
variable and often lack components important to the patient
undergoing HCT. Initiatives for the FinancialWG included the
following:
1. DisseminateWG products and resources to facilitate care
of transplant recipients.
Year 1 efforts focused on (1) development of a set of
model health insurance beneﬁts that should be avail-
able to all patients undergoing HCT, including coverage
for the actual transplantation beneﬁt, search and
procurement beneﬁts, travel, lodging, clinical trial
coverage, and prescription medications, and (2) gener-
ation of a standard authorization form that transplant
centers can submit to all payors to request approval
for search and transplantation on behalf of patients
(accessible online at http://marrow.org/HD/Payor/
Transplant_Reimbursement_Resource_Center.aspx). In
year 2, strategies were activated to distribute
these materials to key audiences, such as small health
plans, self-funded accounts, reinsurers, professional
payor societies, beneﬁt consultants, healthcare profes-
sionals, transplant networks, and HCT program
administrators.
2. Assist transplant centers by clarifying and expanding
medical billing codes for HCT-associated procedures.
It was acknowledged that available codes for trans-
plantation are ambiguous and not comprehensive. A
series of recommendations were identiﬁed to promote
consistency in coding HCT-associated procedures
(eg, search and procurement of a marrow product) and
to clarify existing codes, such as rewording the Current
Procedural Terminology code deﬁnition for donor
leukocyte infusion. The WG determined that it was
critical to proactively review International Statistical
Classiﬁcation of Diseases and Related Health Problems,
10th Revision procedural codes and request appro-
priate new codes as the HCT and cellular therapy ﬁelds
evolve.
3. Continue to support the development of standard
coverage indications for HCT through the Health
Resources and Services Administration Advisory Council
on Blood and Stem Cell Transplantation.
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primary scope of effort of the Financial WG; however,
multiple members of the WG were involved in this
Health Resources and Services Administration effort.
The standard coverage indications for HCT initiative
were deemed critical and central to the HCT ﬁeld,
and provide payors with important evidence-
based guidelines justifying ongoing support for HCT
patients.
Facility Capacity and Care Delivery Model
The following prioritized initiatives focused on assessing
market potential and reducing late referral for HCT through
increased engagement with referring physicians:
1. Assess transplant center market potential.
The NMDP will continue to calculate transplantation
demand and unmet transplantation needs (market
potential) within every US market using Surveillance
Epidemiology and End Results and CIBMTR data.
Thiessen polygon boundaries were constructed that
grouped transplant centers into market areas serving
common patient populations: adult versus pediatric
and malignant versus nonmalignant diseases. An
example of the resulting market areas and associated
unmet needs is shown in Figure 3. These market
potential assessments improve understanding of
individual market barriers and will assist transplant
centers in planning to meet the demand for HCT
within their market. The WG will develop strategies
to disseminate the data to individual transplant
centers.
2. Improve referral timing, rates, and process effectiveness.
The WG will continue to advise the NMDP Medical
Education staff on their initiatives to (1) increase
engagement with US physicians who refer patients for
transplantation; (2) identify transplant centers that
have the highest unmet needs of transplant recipients
by increasing local education outreach to referringFigure 3. Unmet need for allogeneic HCT in US transplant center market areas. The ﬁ
who potentially needed HCT and did not receive one. Each market area is deﬁned b
bisectors of the lines connecting the location of adjacent transplant centers.physicians; (3) implement a new continuing medical
education series focusing on increasing awareness of
the appropriate application of transplantation, patient
eligibility, and the importance of timely planning; and
(4) develop and assess a resource based on published
posttransplantation care consensus guidelines [4] for
referring physicians.
The WG plans to explore the possibility of partnering
with transplant centers and other organizations
(eg, Foundation for the Accreditation of Cellular
Therapy) to address the need for posttransplantation
care plans. This initiative will strengthen transplant
centers’ relationships with physicians providing
posttransplantation care. The WG will continue to
characterize model care delivery practices through
NMDP network transplant center site visits. Model
practices will guide efforts to better reach market
potential for network transplant centers.
Diversity and Health Care Disparities Advisory Group
In collaboration with other WGs, this WG ensured that
issues related to diversity and healthcare disparities were
considered in year 2 deliberations. Speciﬁc recommenda-
tions of this WG include the following:
1. Analysis of US allogeneic HCT markets for minority and
underserved populations.
This initiative will build on the Facilities Capacity and
Care Delivery Model WGmarket assessment project to
map out underserved allogeneic HCT markets in the
United States and will inform policy on patient and
transplant center characteristics within those markets
that may impede access to HCT.
2. Identify funding for short-term education programs to
increase HCT workforce diversity.
Needs assessment survey ﬁndings suggested that early
exposure to the ﬁeld of HCT plays a crucial role in the
decision making process for medical and other health
professional students. The creation of short-termgure shows adult patients (age 20-54, all diagnoses) within each market area
y a Thiessen polygon, in which boundaries are deﬁned by the perpendicular
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example, medical and nursing school presents an
opportunity to mentor high-potential, diverse
students earlier in their academic careers.
3. Provide expertise on diversity- and health disparitye
focused activities.
The WG will continue to provide expertise on SCI
activities that may potentially improve access to
HCT among previously underrepresented groups. For
example, the WG supports the efforts of the Nursing
Workforce WG to recruit nurses from diverse
communities to the HCT ﬁeld by providing culturally
appropriate language and identifying community-
speciﬁc needs for outreach efforts. In addition, the
WG will continue to assess the impact of factors that
contribute to issues of diversity and healthcare
disparities (eg, socioeconomic status) through the
Diversity Metrics Project. This project, implemented in
2011, aims to describe and report on key diversity and
healthcare disparity measures within transplant and
donor recruitment. The continuation of this project
through year 3 will direct reﬁnements in data collec-
tion methods, analysis, and program recommenda-
tions to key stakeholder audiences.
IMPACT
The data collection and analysis from year 2 will be used
to inform implementation strategies and activities in year 3.
To ensure appropriate stewardship of the SCI issues going
forward, strategic activities will be aimed at securing partner
and stakeholder engagement, determining the role of part-
nerships within each initiative, resolving barriers to imple-
mentation, and evaluating progress of the priority initiatives
adopted. Areas for future HCT-related health services and
health policy research identiﬁed during the year 2 deliber-
ations include analyzing HCT market potential, evaluating
the effectiveness of BMTeducation and outreach to students/
fellows, and establishing transplant center benchmarks forstructure, stafﬁng, and care delivery models. To implement
this research agenda, focusing on its translation to practice
and care delivery, it will be critical to sustain existing
collaborations as well as create new partnerships with
HCT-focused organizations, healthcare professionals, and
academic institutions.ACKNOWLEDGMENTS
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